pharmaphorum

SEPTEMBER 11, 2020

Prior to the $63 billion takeover by AbbVie, Allergan’s biggest product was botulinum toxin product Botox, best known as a wrinkle and migraine treatment, and that headed a sizeable medical aesthetics portfolio at the company which also included dermal filler products like Juvederm.

Botox 119

Botox Filler Production Marketing 119

XTalks

JANUARY 20, 2025

While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4 Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing generic drug business.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

XTalks

NOVEMBER 1, 2024

In this blog, we highlight the top 20 best-selling neurology drugs to watch in 2024, based on 2023 sales statistics. We discuss each drug’s approved uses, sales performance and why they’ve become essential in the neurology space. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1.

FDA Approval 85

FDA Approval Drugs Botox Sales 85

pharmaphorum

NOVEMBER 4, 2020

Novartis recorded Aimovig sales of $108 million in the first nine months of 2020, a rise of 44% on the same period of 2019, and says it is the most prescribed drug in the CGRP inhibitor class with 480,000 patients using it worldwide. Both drugs can take up to three months for their effect on migraine prevention to fully kick in.

Botox 96

Botox Sales Doctors Doctor 96

pharmaphorum

NOVEMBER 18, 2020

The decision is based on trials comparing Emgality with placebo which showed that the antibody halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more prior medicines, such as Allergan’s Botox (botulinum toxin type A) or topiramate.

Sales 96

Sales Botox Antibody Drugs 96

pharmaphorum

NOVEMBER 18, 2020

The decision is based on trials comparing Emgality with placebo which showed that the antibody halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more prior medicines, such as Allergan’s Botox (botulinum toxin type A) or topiramate.

Sales 94

Sales Botox Antibody Drugs 94

pharmaphorum

SEPTEMBER 29, 2021

Qulipta (atogepant) is AbbVie’s second oral CGRP inhibitor after Ubrelvy (ubrogepant) – which was approved for the acute treatment of migraine attacks in 2019 – and rounds out a range that also includes the injectable Botox. Botox is prescribed for the prevention of headaches in adults diagnosed with chronic migraine.

Botox 52

Botox Sales Marketing FDA Approval 52